Methocarbamol Tablets, USP 500 mgMethocarbamol Tablets, USP 750 mg Rx Only

Methocarbamol Tablets, USP 500 mgMethocarbamol Tablets, USP 750 mg Rx Only

Drug Labeling and Warnings

Drug Details

k">

METHOCARBAMOL- methocarbamol tablet 
Oxford Pharmaceuticals, LLC

----------

Methocarbamol Tablets, USP 500 mg
Methocarbamol Tablets, USP 750 mg

Rx Only

DESCRIPTION

Methocarbamol Tablets, USP, 500 mg and 750 mg, a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

The chemical name of methocarbamol is 3-(2-methoxyphenoxy)-1, 2-propanediol 1-carbamate and has the empirical formula C11H15NO5. Its molecular weight is 241.24. The structural formula is shown below.

str

Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and n-hexane.

Each tablet, for oral administration, contains either 500 mg or 750 mg of methocarbamol, USP. The inactive ingredients present are colloidal silicon dioxide, magnesium stearate, povidone, pregelatinized corn starch, purified water, sodium starch glycolate, and stearic acid.

CLINICAL PHARMACOLOGY

The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Pharmacokinetics

In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged methocarbamol also are excreted in the urine.

Special populations

Elderly
The mean (± SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean [± SD] age, 69 [± 4] years) was slightly prolonged compared to a younger (mean [± SD] age, 53.3 [± 8.8] years), healthy population (1.5 [±0.4] hours versus 1.1 [± 0.27] hours, respectively). The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41 to 43% versus 46 to 50%, respectively).

Renally impaired
The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean (± SD) elimination half-life in these two groups was similar: 1.2 (± 0.6) versus 1.1 (± 0.3) hours, respectively.

Hepatically impaired
In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 age- and weight-matched normal subjects. The mean (± SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 (±1.62) hours and 1.11 (± 0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared to 46 to 50% in the normal subjects.

INDICATIONS AND USAGE

Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties.

Methocarbamol does not directly relax tense skeletal muscles in man.

CONTRAINDICATIONS

Methocarbamol is contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

WARNINGS

Since methocarbamol may possess a general CNS depressant effect, patients receiving methocarbamol tablets should be cautioned about combined effects with alcohol and other CNS depressants.

Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see PRECAUTIONS, Pregnancy).

Use in Activities Requiring Mental Alertness

Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

PRECAUTIONS

Information for Patients

Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.

Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

Drug Interactions

See WARNINGS and PRECAUTIONS for interaction with CNS drugs and alcohol.

Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

Drug/Laboratory Test Interactions

Methocarbamol may cause a color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.

Pregnancy

Teratogenic Effects – Pregnancy Category C
Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol should be given to a pregnant woman only if clearly needed.

Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see WARNINGS).

Nursing Mothers

Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when methocarbamol is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of methocarbamol in pediatric patients below the age of 16 have not been established.

ADVERSE REACTIONS

Adverse reactions reported coincident with the administration of methocarbamol include:

Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache

Cardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombophlebitis

Digestive system: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting

Hemic and lymphatic system: Leukopenia

Immune system: Hypersensitivity reactions

Nervous system: Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo

Skin and special senses: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria

OVERDOSAGE

Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma.

In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.

Treatment

Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.

DOSAGE AND ADMINISTRATION

Methocarbamol, 500 mg — Adults: Initial dosage: 3 tablets q.i.d.
Maintenance dosage: 2 tablets q.i.d.

Methocarbamol, 750 mg — Adults: Initial dosage: 2 tablets q.i.d.
Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.

Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

HOW SUPPLIED

Methocarbamol Tablets, USP 500 mg — white, round, convex face, debossed “611” over bisect and “O” below bisect on one side and plain on the reverse side. Available in:
bottles of 10, NDC number 69584-611-01
bottles of 100, NDC number 69584-611-10
bottles of 500, NDC number 69584-611-50
bottles of 1000, NDC number 69584-611-90

Methocarbamol Tablets, USP 750 mg — white, capsule shape, convex face, debossed “612” on one side and debossed “O” on the reverse side. Available in:
bottles of 10, NDC number 69584-612-01
bottles of 100, NDC number 69584-612-10
bottles of 500, NDC number 69584-612-50
bottles of 1000, NDC number 69584-612-90

Store at 20°– 25°C (68°– 77°F) [See USP Controlled Room Temperature].

Dispense in tight container.

For more information, call Oxford Pharmaceuticals, LLC at 1-844-508‑1455, 8:00 am - 6:00 pm CT, Monday – Friday

Manufactured by:
OXFORD PHARMACEUTICALS
Birmingham, AL 35211

8200004
Rev 01/19
R00

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC: 69587-611-10

METHOCARBAMOL
TABLETS, USP
500 mg

Rx only
100 TABLETS


EACH TABLET CONTAINS:
Methocarbamol, USP … 500 mg

DOSAGE: See package insert for full prescribing information.

DISPENSE in a tight container

STORE at 20 to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Manufactured by:
OXFORD
PHARMACEUTICALS, LLC
BIRMINGHAM, AL 35211
Rev. 05/19 R00
8000021

500 mg

NDC: 69587-612-10

METHOCARBAMOL
TABLETS, USP
750 mg

Rx only
100 TABLETS


EACH TABLET CONTAINS:
Methocarbamol, USP … 750 mg

DOSAGE: See package insert for full prescribing information.

DISPENSE in a tight container

STORE at 20 to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Manufactured by:
OXFORD
PHARMACEUTICALS, LLC
BIRMINGHAM, AL 35211
Rev. 05/19 R00
8000024

750 mg

METHOCARBAMOL 
methocarbamol tablet
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 69584-611
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Methocarbamol (UNII: 125OD7737X) (Methocarbamol - UNII:125OD7737X) Methocarbamol500 mg
Inactive Ingredients
Ingredient NameStrength
Silicon Dioxide (UNII: ETJ7Z6XBU4)  
Magnesium Stearate (UNII: 70097M6I30)  
Povidone K90 (UNII: RDH86HJV5Z)  
Starch, Corn (UNII: O8232NY3SJ)  
Water (UNII: 059QF0KO0R)  
Sodium Starch Glycolate Type A Potato (UNII: 5856J3G2A2)  
Stearic Acid (UNII: 4ELV7Z65AP)  
Product Characteristics
ColorWHITEScore2 pieces
ShapeROUNDSize13mm
FlavorImprint Code 611;O
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC: 69584-611-0110 in 1 BOTTLE; Type 0: Not a Combination Product08/15/2019
2NDC: 69584-611-10100 in 1 BOTTLE; Type 0: Not a Combination Product08/15/2019
3NDC: 69584-611-50500 in 1 BOTTLE; Type 0: Not a Combination Product08/15/2019
4NDC: 69584-611-901000 in 1 BOTTLE; Type 0: Not a Combination Product08/15/2019
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA04048908/15/2019
METHOCARBAMOL 
methocarbamol tablet
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 69584-612
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Methocarbamol (UNII: 125OD7737X) (Methocarbamol - UNII:125OD7737X) Methocarbamol750 mg
Inactive Ingredients
Ingredient NameStrength
Silicon Dioxide (UNII: ETJ7Z6XBU4)  
Magnesium Stearate (UNII: 70097M6I30)  
Povidone K90 (UNII: RDH86HJV5Z)  
Starch, Corn (UNII: O8232NY3SJ)  
Water (UNII: 059QF0KO0R)  
Sodium Starch Glycolate Type A Potato (UNII: 5856J3G2A2)  
Stearic Acid (UNII: 4ELV7Z65AP)  
Product Characteristics
ColorWHITEScoreno score
ShapeCAPSULESize19mm
FlavorImprint Code 612;O
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC: 69584-612-0110 in 1 BOTTLE; Type 0: Not a Combination Product08/15/2019
2NDC: 69584-612-10100 in 1 BOTTLE; Type 0: Not a Combination Product08/15/2019
3NDC: 69584-612-50500 in 1 BOTTLE; Type 0: Not a Combination Product08/15/2019
4NDC: 69584-612-901000 in 1 BOTTLE; Type 0: Not a Combination Product08/15/2019
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA04048908/15/2019
Labeler - Oxford Pharmaceuticals, LLC (079638266)
Establishment
NameAddressID/FEIBusiness Operations
Oxford Pharmaceuticals, LLC079638266manufacture(69584-611, 69584-612)

Revised: 7/2019
 
Oxford Pharmaceuticals, LLC


© 2020 FDA.report
This site is not affiliated with or endorsed by the FDA.